# Table of Contents

**Clinical Guidelines**

- AASLD/IDSA HCV Guidelines ........................................................................................................ 4
- AIDS Institute – New York State Dept of Health Clinical Guidelines ............................................. 4
- CDC STI Treatment Guidelines ...................................................................................................... 4
- HIVinfo | Information on HIV/AIDS Treatment, Prevention and Research | NIH ............................ 5
- HIV Info: 51 Fact Sheets ................................................................................................................ 5
- HIVinfo: 19 infographics ................................................................................................................ 6
- HIVinfo: HIV/AIDS Awareness Days ............................................................................................. 7
- HIVinfo: Research Information ......................................................................................................... 7
- HIVinfo: HIV Source ........................................................................................................................ 7
- HIVinfo Contact Information ........................................................................................................... 8
- HIV/AIDS Treatment Guidelines | Clinicalinfo.HIV.gov ................................................................... 8
- HIV/AIDS Drugs | NIH ....................................................................................................................... 8
- HIV/AIDS Glossary | NIH .................................................................................................................. 8
- IDSA Practice Guidelines ............................................................................................................... 8
- IDSA Primary Care Guidance for Persons With HIV ...................................................................... 9

**PrEP Guidelines**

- CDC Guidelines for HIV Prevention (PrEP, OPEP, nPEP) .............................................................. 9
- New York State DOH AIDS Institute PrEP Guidelines .................................................................. 10

**PEP Guidelines**

- CDC and US Public Health Service: Updated Guidelines for ARV PEP after Sexual, Injection Drug Use, or other Nonoccupational Exposure to HIV_US_2016 ................................................................................................................ 10
- CDC and US Public Health Service: Updated Guidelines for Management of Occupational Exposures to HIV and Recommendations for PEP_2018 .............................................................................................................. 10
New York State DOH AIDS Institute PEP to Prevent HIV Infection .......................................................... 10

Substance Use Resources ......................................................................................................................... 10
HIV Research Program (HRP) | National Institute on Drug Abuse (NIDA) (nih.gov) ......................... 10
SAMHSA TIP 37: Substance Abuse Treatment for Persons With HIV/AIDS ....................................... 10
SAMHSA Drugs, Alcohol and HIV/AIDS: A Consumer Guide .......................................................... 11
Syringe Services Programs (SSPs) | CDC ................................................................................ 11
Syringe Services Programs Technical Package (cdc.gov) .................................................................... 11

Transgender Care Guidelines .................................................................................................................. 12
UCSF Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People .......................................................................................................................... 12
World Professional Association for Transgender Health Standards of Care Version 8 ..................... 12
Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society*
Clinical Practice Guideline .................................................................................................................. 12
Fenway Health: Trans Health Program and Gender Affirming Care ................................................. 13

Clinical Resources ................................................................................................................................. 13
HIV Assist............................................................................................................................................. 13
Stanford University HIV Drug Resistance Database ............................................................................. 13
University of Liverpool Drug interactions Checker ................................................................................ 14

Consultation Services (Warmlines) ......................................................................................................... 14
National Clinicians Consultation Center(s) ............................................................................................ 14
The National Network of STD Clinical Prevention Training Centers ................................................. 15

CME/CE Curricula .................................................................................................................................... 15
ACTHIV® Institute ................................................................................................................................. 15
AAHIVM .................................................................................................................................................. 15
AETC ....................................................................................................................................................... 15
CDC Clinician Outreach and Communication Activity (COCA) ....................................................... 15
IAS-USA .................................................................................................................................................. 16
HIVMA/IDSA .......................................................................................................................................... 16
Journal Watch ID ................................................................................................................................. 17
MMWR .................................................................................................................................................... 17
National AIDS Curriculum .................................................................................................................... 17
National STD Curriculum ...................................................................................................................... 18
NY Clinical Education Initiative ........................................................................................................... 18

Resources for the HIV Care Team (Ver 4.24.2023)
### Professional Organizations

- AAHIVM ................................................................. 18
- ANAC ................................................................. 19
- HIVMA/IDSA .......................................................... 19

### Major Meetings

- ACTHIV® - American Conference for the Treatment of HIV® ............................................. 20
- AIDS - The International AIDS Conference ............................................................................ 20
- CROI ................................................................................................................................. 20
- IDWeek ............................................................................................................................ 21
- International AIDS Society ................................................................................................. 21
- The Ryan White HIV/AIDS Program Clinical Conference ..................................................... 21
Clinical Guidelines

AASLD/IDSA HCV Guidelines

- Quick view: American Association for the Study of Liver Diseases and Infectious Diseases Society of America HCV treatment guidelines
- Description
  - New direct-acting antiviral agents (DAAs) capable of curing hepatitis C virus (HCV) infection have been approved for use in the United States. The initial DAAs were approved in 2011 and many others have since followed, including 2 new pangenotypic regimens in 2017. As new information is presented at scientific conferences and published in peer-reviewed journals, health care practitioners have expressed a need for a credible source of unbiased guidance on how best to treat their patients with HCV infection. To provide healthcare professionals with timely guidance, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) have developed a web-based process for the rapid formulation and dissemination of evidence-based, expert-developed recommendations for hepatitis C management. New sections will be added, and the recommendations will be updated on a regular basis as new information becomes available.

AIDS Institute – New York State Dept of Health Clinical Guidelines

- Quick view: Clinical practice guidelines that include HIV Testing & Acute HIV, ART, primary HIV care, perinatal HIV care, PrEP, PEP, hepatitis, STI, and substance use
- Description
  - The New York State Department of Health (NYSDOH) AIDS Institute (AI) Clinical Guidelines Program is a longstanding, collaborative effort of the AI Office of the Medical Director and the Johns Hopkins University School of Medicine, Division of Infectious Diseases.
  - The program produces and publishes evidence-based, state-of-the-art clinical practice guidelines that establish uniform standards of care for NYS to improve the health and well-being of all adults who receive prevention services or treatment for HIV, viral hepatitis, other sexually transmitted infections, and substance use disorders.

CDC STI Treatment Guidelines

- Quick view: 2021 STI Treatment Guidelines from CDC
- Description
  - CDC’s Sexually Transmitted Infections (STI) Treatment Guidelines, 2021 provides current evidence-based prevention, diagnostic and treatment recommendations that replace the 2015 guidance. The recommendations are intended to be a source for clinical guidance. Healthcare providers should always assess patients based on their clinical circumstances and local burden.
**HIVinfo | Information on HIV/AIDS Treatment, Prevention and Research | NIH**

- **Quick view:** Comprehensive federal HIV clinical resources.
  - HIVinfo features the Understanding HIV components including easy-to-understand fact sheets and infographics.
  - Clinicalinfo features the HIV Clinical Treatment Guidelines, the HIV Drug Database, and the Glossary.
  - Both sites feature Spanish pages that can be accessed using the Spanish (es) dropdown

- **Description**
  - Formerly known as AIDSInfo; since September 2020 the websites have been renamed [HIVinfo.NIH.gov](https://HIVinfo.NIH.gov) and [Clinicalinfo.HIV.gov](https://Clinicalinfo.HIV.gov)

**HIV Info: 51 Fact Sheets**

- **HIV Overview**
  - HIV and AIDS: The Basics
  - The HIV Life Cycle
  - The Stages of HIV Infection
  - What is a Latent HIV Reservoir?
  - HIV Testing
  - FDA-Approved HIV Medicines
  - What is an Investigational HIV Drug?
  - What is a Therapeutic HIV Vaccine?
  - What is a Preventive HIV Vaccine?
  - HIV and AIDS Clinical Trials

- **HIV Prevention**
  - The Basics of HIV Prevention
  - Preventing Perinatal Transmission of HIV
  - Pre-Exposure Prophylaxis (PrEP)
  - Post-Exposure Prophylaxis (PEP)

- **HIV Treatment**
  - HIV Treatment: The Basics
  - Just Diagnosed: Next Steps After Testing Positive for HIV
  - When to Start HIV Medicines
  - What to Start: Choosing an HIV Treatment Regimen
  - FDA-Approved HIV Medicines
  - Drug Resistance
  - HIV Treatment Adherence
  - Following an HIV Treatment Regimen: Steps to Take Before and After Starting HIV Medicines
  - What is a Drug Interaction?
  - HIV and Immunizations
• Side Effects of HIV Medicines
  o HIV Medicines and Side Effects
  o HIV and Diabetes
  o HIV and Hepatotoxicity
  o HIV and High Cholesterol
  o HIV and Lactic Acidosis
  o HIV and Lipodystrophy
  o HIV and Osteoporosis
  o HIV and Rash

• HIV and Pregnancy
  o Preventing Perinatal Transmission of HIV
  o HIV Medicines During Pregnancy and Childbirth
  o Preventing Perinatal Transmission of HIV After Birth

• HIV and Specific Populations
  o HIV and Children and Adolescents
  o HIV and Women
  o HIV and Gay and Bisexual Men
  o HIV and Older People

• HIV and Opportunistic Infections, Coinfections, and Conditions
  o What is an Opportunistic Infection?
  o HIV and COVID-19
  o HIV and Hepatitis B
  o HIV and Hepatitis C
  o HIV and Tuberculosis (TB)
  o HIV and Sexually Transmitted Diseases (STDs)
  o HIV and Heart Disease
  o HIV and Kidney Disease

• Living with HIV
  o How to Find HIV Treatment Services
  o HIV and Mental Health
  o HIV and Nutrition and Food Safety
  o HIV and Substance Use

HIVinfo: 19 infographics
• Antiretroviral Therapy: What Does it Do?
• HIV and AIDS: What’s The Difference?
• PrEP vs. PEP
• Tips for HIV Treatment Regimen Adherence
• FDA Approval of HIV Medicines
• HIV and Birth Control
• Protecting Baby from HIV
• What Do My Lab Results Mean?
• HIV Drug Resistance
• HIV-Discordant Couples
• The Path to a Longer, Healthier Life with HIV
• What’s a Blip?
• HIV Life Cycle
• Living with HIV: Steps to Better Health
• Therapeutic HIV vaccines
• Who’s on Your Team?
• Pets and People with HIV
• Three Things to Know about HIV Treatment
• You Can Safely Share...With Someone With HIV

**HIVinfo: HIV/AIDS Awareness Days**

- Collection of HIV/AIDS Awareness days throughout the year and additional information about each.

**HIVinfo: Research Information**

- HIV-related research information from the NIH, including clinical trials

**HIVinfo: HIV Source**

- Portal for HIV-related information from within and outside the Federal government
  - Basic HIV/AIDS Information
  - Community Engagement
  - Funding Opportunities
  - HIV Navigation Resources
  - HIV Prevention
  - HIV Treatment
  - HIV-Related Conditions
  - HIV and AIDS Policies and Organizational Programs
HIVinfo Contact Information

- **Phone**
  - 1-800-HIV-0440 (1-800-448-0440)
  - Monday to Friday, 1:00 p.m. to 4:00 p.m. Eastern Time
  - English- and Spanish-speaking health information specialists from the Office of AIDS Research are available.

- **Email**
  - HIVinfo@NIH.gov
  - Inquiries answered from the Office of AIDS Research in the order received.
  - Most inquiries are answered within 5 working days. English- and Spanish-language email inquiries will be answered.

- **Newsletter**
  - HIVinfo@govdelivery.com

HIV/AIDS Treatment Guidelines | Clinicalinfo.HIV.gov

- **Quick view:** Continually updated, federally approved clinical practice guidelines for HIV/AIDS
- **Description:**
  - Developed by panels of experts in HIV care
  - Panels are working groups of the NIH Office of AIDS Research Advisory Committee

HIV/AIDS Drugs | NIH

- **Quick view:** Comprehensive HIV drug database
- **Description:**
  - Information on HIV-related drugs, including FDA-approved antiretroviral and opportunistic infection drugs and investigational drugs.
  - Entries for 152 drugs in English and Spanish.

HIV/AIDS Glossary | NIH

- **Quick view:** Definitions for ~1,060 terms related to HIV/AIDS in English and Spanish.

IDSA Practice Guidelines

- **Quick view:** 54 current clinical practice guidelines, listed alphabetically and by organ system
- **Description**
  - IDSA Clinical Practice Guidelines are developed by a panel of experts who perform a systematic review of the available evidence and use the GRADE process to develop evidence-based recommendations to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances.
  - IDSA Clinical Guidance documents are developed based on a comprehensive (but not necessarily systematic) review of the available evidence, coupled with experience of
clinical and research experts on the topic. They do not include a formal grading of the evidence. Over time, IDSA Guidance documents may be transitioned to a clinical practice guideline.

**IDSA Primary Care Guidance for Persons With HIV**

- **Quick view:** Guidance from an expert panel of the HIV Medicine Association of the Infectious Diseases Society of America updates previous 2013 primary care guidelines
- **Description**
  - To receive optimal medical care and achieve desired outcomes, persons with HIV must be consistently engaged in care and able to access uninterrupted treatment, including ART.
  - Comprehensive evidence-based HIV primary care guidance is, therefore, more important than ever. Creating a patient-centered, stigma-free care environment is essential for care engagement.
  - Barriers to care must be decreased at the societal, health system, clinic, and individual levels. As the population ages and noncommunicable diseases arise, providing comprehensive healthcare for persons with HIV becomes increasingly complex, including management of multiple comorbidities and the associated challenges of polypharmacy, while not neglecting HIV-related health concerns.
  - Clinicians must address issues specific to persons of childbearing potential, including care during preconception and pregnancy, and to children, adolescents, and transgender and gender-diverse individuals.

**PrEP Guidelines**

**CDC Guidelines for HIV Prevention (PrEP, OPEP, nPEP)**

- **Quick view:** Resource list of all CDC PrEP, PEP Guidelines

**CDC and USPHS: PrEP for the Prevention of HIV Infection in the US _2021 update_**

- **Quick view:** Updated federal PrEP Guidelines
- **Description:** The Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2021 Update – A Clinical Practice Guideline includes revisions to several sections. These revisions are intended to update existing guidance using the current evidence base, to incorporate recent FDA PrEP medication approvals, and to clarify specific aspects of clinical care. Other revisions were made to improve usability and increase implementation of the guideline based on comments received from clinicians providing PrEP care.

- Quick view: Provider materials to accompany the 2021 USPHS and CDC PrEP Guidelines update

New York State DOH AIDS Institute PrEP Guidelines

- Quick view: PrEP guidance New York State. Includes pocket guide, printable slides, printable pdf, provider checklists, insurance and other coverage information

PEP Guidelines

CDC and US Public Health Service: Updated Guidelines for ARV PEP after Sexual, Injection Drug Use, or other Nonoccupational Exposure to HIV_US_2016

- Quick view: PEP Guidance for non-occupational HIV exposure

CDC and US Public Health Service: Updated Guidelines for Management of Occupational Exposures to HIV and Recommendations for PEP_2018

- Quick view: PEP Guidance for occupational HIV exposure

New York State DOH AIDS Institute PEP to Prevent HIV Infection

- Quick view: PEP guidance New York State. Includes occupational, non-occupational, sexual assault, exposure risk in children

Substance Use Resources

HIV Research Program (HRP) | National Institute on Drug Abuse (NIDA) (nih.gov)

- Quick view: Overview of high priority research at the intersection of HIV, substance use, and substance use disorders, across the federal government and with communities

SAMHSA TIP 37: Substance Abuse Treatment for Persons With HIV/AIDS

- Quick view: Substance Abuse and Mental Health Services Administration clinical guidance for HIV and substance use disorders
- Description: This manual helps clinicians improve care for people living with HIV/AIDS and substance use disorder conditions. It discusses prevention, assessment, and treatment of HIV/AIDS. The manual also examines mental illness, integrated services, case management, counseling, ethical and legal issues, and funding sources.
SAMHSA Drugs, Alcohol and HIV/AIDS: A Consumer Guide

- **Quick view:** Substance Abuse and Mental Health Services Administration brochure for clients
- **Description:** This brochure promotes awareness and prevention of HIV/AIDS among people living with substance use disorders. It explains the link between substance misuse and HIV/AIDS, underlines the importance of treatment, and offers a list of resources.


- **Quick view:** Substance Abuse and Mental Health Services Administration for African American clients
- **Description:** This guide provides information for African American consumers on the link between HIV/AIDS and substance use. It explains the increased risk of HIV transmission and the importance of treatment for alcohol and substance misuse and HIV/AIDS.

Syringe Services Programs (SSPs) | CDC

- **Quick view:** CDC overview of SSPs
- **Description:**
  - Syringe services programs (SSPs) are community-based prevention programs that can provide a range of services, including linkage to substance use disorder treatment; access to and disposal of sterile syringes and injection equipment; and vaccination, testing, and linkage to care and treatment for infectious diseases.
  - SSPs protect the public and first responders by facilitating the safe disposal of used needles and syringes. Providing testing, counseling, and sterile injection supplies also helps prevent outbreaks of other diseases.

Syringe Services Programs Technical Package (cdc.gov)

- **Quick view:** CDC Technical Package of Effective Strategies and Approaches for Planning, Design, and Implementation of SSPs
- **Description:** This technical package is a resource for use by health departments, community-based organizations, and diverse stakeholders to guide effective SSP design, implementation, and service delivery.
Transgender Care Guidelines

UCSF Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People
- Quick view: UCSF clinical guidelines for primary care for transgender and gender non-binary persons
- Description: Guidelines aim to address disparities by equipping primary care providers and health systems with the tools and knowledge to meet the health care needs of their transgender and gender nonconforming patients. These guidelines expand on the original UCSF Primary Care Protocol for Transgender Care

World Professional Association for Transgender Health Standards of Care Version 8
- Quick view: Promotes the highest standards of health care for individuals through the articulation of Standards of Care (SOC) for the Health of Transsexual, Transgender, and Gender Nonconforming People.
- Description:
  - Clinical guidance for health professionals to assist transsexual, transgender, and gender nonconforming people with safe and effective pathways to achieving lasting personal comfort with their gendered selves, in order to maximize their overall health, psychological well-being, and self-fulfillment.
  - This assistance may include primary care, gynecologic and urologic care, reproductive options, voice and communication therapy, mental health services (e.g., assessment, counseling, psychotherapy), and hormonal and surgical treatments.
  - While this is primarily a document for health professionals, the SOC may also be used by individuals, their families, and social institutions to understand how they can assist with promoting optimal health for members of this diverse population.

Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline
- Quick view: Journal of Clinical Endocrinology and Metabolism clinical practice guideline for endocrine treatment for transgender persons
- Description:
  - Gender affirmation is multidisciplinary treatment in which endocrinologists play an important role.
  - Gender-dysphoric/gender-incongruent persons seek and/or are referred to endocrinologists to develop the physical characteristics of the affirmed gender
Fenway Health: Trans Health Program and Gender Affirming Care

- **Quick view:** Fenway Health guidance for transgender health and gender affirming care
- **Description:** Integrated model to provide all aspects of care through an affirming, trauma-informed model.

Clinical Resources

HIV Assist

- **Quick view:** HIV Assist allows entry of patient’s known resistance and other patient attributes to suggest optimal ART
- **Description**
  - HIV-ASSIST utilizes a multi-criteria decision analysis framework to rank a large number of 2, 3, and 4 drug combinations based on specific patient attributes (drug resistance, comorbidities, comedications, treatment history, viral load, CD4, tropism, HLA status).
  - HIV-ASSIST algorithms result in an aggregate "Weighted Utility Score," constructed on a scale of 0-10+ (or higher in some case), where lower numbers are more 'preferred' regimens. The outcome of interest is an aggregate of likelihood of viral suppression (e.g., drug activity) and tolerability (e.g., minimize drug interactions, impact on comorbidities, pill burden).

Stanford University HIV Drug Resistance Database

- **Quick view:** The HIVDB program allows for entry of a patient’s HIV genotype results and predicts drug resistance for that patient with an explanation.
- **Description**
  - The presence of HIVDR prior to the start of an ARV-treatment regimen is a strong predictor of the success or failure of that regimen. Genotypic resistance testing using DNA sequencing is performed routinely in upper-income countries before patients start ARV therapy and in patients who develop virologic failure during treatment. In low- and middle-income countries (LMICs) it is used sparingly but with increasing frequency. Interpreting HIV genotypic resistance tests is difficult because there are many different DRMs, which occur in complex patterns and which have diverse effects on the ARVs within each drug class.
  - HIVDB contains a free publicly available genotypic resistance interpretation system that can be accessed via an HTML or an automated web service. The interpretation system has been integrated into the workflows of the World Health Organization’s HIV drug resistance network, the NIH-funded AIDS Clinical Trials Group, and several hundred research and clinical laboratories worldwide. Several thousand clinicians also use the program’s HTML interface each month to help choose the most appropriate treatment for their patients. The interpretation system is accompanied by detailed mutation penalties and comments and HIVDR notes for each of the ARV classes as outlined in the system’s Release Notes and Primer.
University of Liverpool Drug interactions Checker

- **Quick view:** freely available drug-drug interaction resource; app is very useful for checking interactions on the fly in clinic or on the wards.
- **Description**
  - Around 37 million individuals are living worldwide with HIV and although advances in therapy have yielded effective regimens, individual antiretroviral drugs are amongst the most therapeutically risky for drug-drug interactions (DDI) presenting significant risks to patients and a challenge for health care providers to ensure safe and appropriate prescribing. In order to address this, the Liverpool Drug Interactions website was established in 1999 by members of the Department of Pharmacology at the University of Liverpool to provide a freely available drug-drug interaction resource.

Consultation Services (Warmlines)

National Clinicians Consultation Center(s)

- **Description**
  - The National Clinician Consultation Center provides rapid expert consultation and advice on management of HIV/AIDS, perinatal HIV, pre-exposure prophylaxis, and post-exposure prophylaxis management for HIV and hepatitis B and C (as well as substance use management). Our clinical consultants are HIV-treatment experienced physicians, clinical pharmacists, nurses, and NPs from the University of California, San Francisco.

  **HIV/AIDS Management:** (800) 933-3413
  9 a.m. – 8 p.m. ET Monday – Friday

  **Perinatal HIV/AIDS:** (888) 448-8765
  24 hours Seven days a week

  **PEP: Post-Exposure Prophylaxis:** (888) 448-4911

  **Occupational PEP**
  11 a.m. – 8 p.m. ET, seven days a week

  **Non-occupational PEP**
  9 a.m. – 8 p.m. ET, Monday – Friday,
  11 a.m. – 8 p.m. ET, weekends & holidays

  **PrEP: Pre-Exposure Prophylaxis:** (855) 448-7737 or (855) HIV-PrEP
  9 a.m. – 8 p.m. ET Monday – Friday

  **Hepatitis C Management:** (844) 437-4636 or (844) HEP-INFO
  9 a.m. – 8 p.m. ET Monday – Friday
The National Network of STD Clinical Prevention Training Centers

- **Description:** The NNPTC’s free Clinical Consultation Network provides STI clinical consultation services within 1-3 business days, depending on urgency, to healthcare providers across the United States.

CME/CE Curricula

ACTHIV® Institute

- **Description**
  - Online education throughout the year focused on meeting the needs of the interprofessional frontline HIV care team.
  - STEP-HIV initiative provides CME/CE-accredited activities designed to support the needs of newer providers as well as those who see smaller panels of persons with HIV.

AAHIVM

- **Description**
  - The American Academy of HIV Medicine (AAHIVM)’s Clinical Education Center serves as a digital, dynamic clearinghouse for AAHIVM-produced medical education programs and resources including self-paced courses, as well as live and archived events.

AETC

- **Description**
  - The AIDS Education and Training Center (AETC) Program is the training arm of the Ryan White HIV/AIDS Program.
  - The AETC Program is a national network of leading HIV experts who provide locally-based, tailored education, clinical consultation and technical assistance to healthcare professionals and healthcare organizations to integrate high quality, comprehensive care for those with or affected by HIV. HIV care is a complex, challenging field, and ongoing, high-quality training and support are essential for clinicians caring for people with HIV.

CDC Clinician Outreach and Communication Activity (COCA)

- **Description**
  - Clinician Outreach and Communication Activity (COCA) provides timely, accurate, and credible information to clinicians related to emergency preparedness and response and
emerging public health threats. COCA fosters partnerships with national clinician organizations to strengthen information-sharing networks before, during, and after a public health emergency.

- COCA serves a wide range of clinical professionals, including: physicians, nurses, physician’s assistants, pharmacists, paramedics, veterinarians, epidemiologists, public health practitioners, and state and local health department officials. In addition, COCA collaborates with national clinician organizations, which in turns allows for extended outreach to a large number of clinicians.
- COCA invites all clinicians to Sign-Up for COCA Email Updates and Reminders.

**IAS-USA**

- **Description**
  - The mission of the International Antiviral Society–USA (IAS–USA) is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.
  - The IAS–USA has a clearly defined mission and an extensive network of experienced and committed experts in the management of HIV and other viral infections and is recognized for high-quality, independent educational programs. The primary educational and informational programs sponsored by the IAS–USA include CME Courses, development of Practice Guidelines, and electronic publication of the peer-reviewed journal Topics in Antiviral Medicine.
  - The IAS–USA serves as the Conference Organizer for the logistical planning and organization for the Conference on Retroviruses and Opportunistic Infections (CROI). For more information about the CROI conference, please visit www.CROIconference.org.
  - The IAS–USA is not affiliated with the International AIDS Society (IAS), an international organization of members working in HIV/AIDS.

**HIVMA/IDSA**

- **Description**
  - HIV Medicine Association is a community of health care professionals that advance a comprehensive and humane response to the HIV pandemic, informed by science and social justice. Membership connects health care professionals practicing HIV medicine to our broader community of ID and to our collective voice that speaks authoritatively on issues facing health care providers, researchers, and their patients. From prevention, access to treatment, and clinical guidelines, to funding for HIV research, the Ryan White Program, and building the HIV workforce: together as HIVMA we act for a comprehensive and humane response to the HIV pandemic and we invite you to join in our work.
  - HIVMA Resource Directory for HIV Clinicians and Educators
  - HIVMA Primary Care Guidance for Persons with HIV: 2020 Update
Journal Watch ID

- **Description**
  - NEJM Journal Watch equips today's caregivers with the information and perspective needed to be clinically prepared and practice with confidence. NEJM Journal Watch is used by practicing clinicians — physicians, nurses, physician assistants, nurse practitioners, residents, students, pharmacists, and other healthcare professionals - to stay informed and current in their fields. The most important research, medical news, drug information, public health alerts, and guidelines across 12 specialties are summarized and put into perspective for you by our team of physician editors.
  - Because context is often as important as the content itself, NEJM Journal Watch always delivers the latest medical research developments in a clinically relevant context. All of our research summaries are accompanied by expert commentary from our contributing physicians, offering a unique perspective about the research itself and how it applies to the everyday practice of medicine. Clinicians who rely on the insights and expert summaries provided by NEJM Journal Watch are among the most informed and best prepared in their fields.

**MMWR**

- **Description**
  - The Morbidity and Mortality Weekly Report (MMWR) series is prepared by the Centers for Disease Control and Prevention (CDC).
  - Often called “the voice of CDC,” the MMWR series is the agency’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations.
  - MMWR readership predominantly consists of physicians, nurses, public health practitioners, epidemiologists and other scientists, researchers, educators, and laboratorians.
  - All material in the MMWR series is in the public domain and may be used and reprinted without special permission; citation as to source, however, is appreciated.
  - Online continuing education (CE) credits are available for selected journal articles.

**National AIDS Curriculum**

- **Description**
  - The National HIV Curriculum is a free educational website from the University of Washington. This project is funded by the Health Resources and Services Administration (HRSA).
  - The National HIV Curriculum provides ongoing, up-to-date information needed to meet the core competency knowledge for HIV prevention, screening, diagnosis, and ongoing treatment and care to healthcare providers in the United States.
Free CME credit, MOC points, CNE contact hours, and CE contact hours are offered throughout this site. Pharmacology CE for advanced practice nurses is also available for many of the activities.

**National STD Curriculum**

- **Description**
  - The National STD Curriculum is a free educational website from the University of Washington STD Prevention Training Center. This project is funded by the CDC.
  - This site addresses the epidemiology, pathogenesis, clinical manifestations, diagnosis, management, and prevention of STDs.
  - Free CME credit and CNE/CE contact hours are offered throughout this site. Pharmacology CE for advanced practice nurses is also available for many activities.

**NY Clinical Education Initiative**

- **Description**
  - Clinical Education Initiative (CEI), a New York State Department of Health AIDS Institute program, is designed to enhance the capacity of New York’s diverse healthcare workforce to deliver clinical services to improve health outcomes related to HIV, Sexual Health, Hepatitis C (HCV) and Drug User Health (DUH). The aims of CEI are fourfold:
    - Educate clinicians by providing continuous and innovative HIV, Post-Exposure Prophylaxis/Pre-Exposure Prophylaxis (PEP/PrEP), HCV, sexual (STIs) and drug user health trainings.
    - Expand the base of providers able to diagnose and care for patients impacted by HIV, HCV, STIs, and DU.
    - Disseminate AIDS Institute clinical practice guidelines, other relevant materials, and resources.
    - Foster partnerships among community-based providers, affiliated organizations, and HIV, HCV, STI and DUH specialists.

**Professional Organizations**

**AAHIVM**

- **Description**
  - The American Academy of HIV Medicine (AAHIVM) is the nation’s leading independent organization of healthcare professionals dedicated to providing excellence in HIV care and prevention. Our membership of practitioners and credentialed clinicians manage the health of the majority of people with and at risk for HIV in the United States. The Academy’s mission is to ensure healthcare professionals have the resources needed to provide prevention, treatment and care for those with or at risk for HIV and related conditions to achieve optimal health.
- AAHIVM Membership: https://aahivm.org/membership/
- AAHIVM HIV Specialist and HIV Pharmacist credentialing programs: https://aahivm.org/credentialing/
- AAHIVM’s quarterly magazine, the HIV Specialist: https://aahivm.org/hiv-specialist-magazine/

**ANAC**

- **Description**
  - The Association of Nurses in AIDS Care (ANAC) is the leading health care organization responding to HIV/AIDS. Since its founding in 1987, ANAC has been meeting the needs of nurses and other healthcare professionals in HIV/AIDS care, research, prevention and policy.
  - ANAC aims to promote the health and welfare of people affected by HIV/AIDS by:
    - Creating an effective, engaged network of nurses in AIDS care
    - Studying, researching and exchanging information, experiences and ideas leading to improved care and prevention
    - Providing leadership to the nursing community in matters related to HIV/AIDS infection and its co-morbidities
    - Advocating for effective public policies and quality care for people living with HIV
    - Promoting social awareness concerning issues related to HIV/AIDS
    - Inherent in these goals is the commitment to the prevention of HIV infection.
    - ANAC is made up of more than 40 chapters located around the world. It comprises a dedicated group of nurses, healthcare professionals and others from around the world who are committed to HIV/AIDS nursing. These affiliate members include social workers, pharmacists, physician assistants, lawyers and doctors; i.e. anyone involved in the care and support of people with HIV and/or AIDS.

**HIVMA/IDSA**

- **Description**
  - HIV Medicine Association (HIVMA) is a community of health care professionals that advance a comprehensive and humane response to the HIV pandemic, informed by science and social justice. Membership connects health care professionals practicing HIV medicine to our broader community of ID and to our collective voice that speaks authoritatively on issues facing health care providers, researchers, and their patients. From prevention, access to treatment, and clinical guidelines, to funding for HIV research, the Ryan White Program, and building the HIV workforce: together as HIVMA we act for a comprehensive and humane response to the HIV pandemic and we invite you to join in our work.
  - Joining the IDSA/HIVMA includes membership in both organizations and subscriptions to the Journal of Infectious Disease and Clinical Infectious Disease
Major Meetings

**ACTHIV® - American Conference for the Treatment of HIV®**

- **Description**
  - The American Conference for the Treatment of HIV® (ACTHIV®) is the premier conference in the US dedicated exclusively to the frontline interprofessional care team and its members who are caring for persons with or at risk of acquiring HIV. The conference delivers information on new developments and research findings that can be rapidly translated and directly applied to the clinical setting.

**AIDS - The International AIDS Conference**

- **Description**
  - The International AIDS Conference is the premier global platform to advance the HIV response. As the world’s largest conference on HIV and AIDS, it sits uniquely at the intersection of science, advocacy and human rights, bringing together scientists, policy makers, healthcare professionals, people living with HIV, funders, media and communities. Since its start in 1985, the conference has served as an opportunity to strengthen policies and programmes that ensure an evidence-based response to HIV and related epidemics.
  - AIDS 2024, the 25th International AIDS Conference, will take place in Munich, Germany, and virtually from 22 to 26 July 22-26, 2024.

**CROI**

- **Description**
  - The Conference on Retroviruses and Opportunistic Infections (CROI) was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research. The best and most consequential original research defines the science at CROI, including research in HIV, hepatitis viruses, SARS-CoV-2, monkeypox, and other viral infections and their related conditions.
  - The 31st Conference on Retroviruses and Opportunistic Infections will be March 3 through 6, 2024, in Denver.
### IDWeek

- **Description**
  
  - IDWeek is a forum for health professionals of varied backgrounds to collaborate, cooperate, and learn from each other’s expertise. With so many common issues and challenges cutting across our four disciplines, IDWeek provides an opportunity to learn from each other’s knowledge, experience and expertise, for the improvement of patient care and public health.
  
  - IDWeek 2023 will be held in Boston, MA, Oct. 11-15 at the Boston Convention and Exhibition Center. IDWeek 2023 will be a hybrid conference.

### International AIDS Society

- **Description**
  
  - The IAS Conference on HIV Science is the world’s most influential meeting on HIV research and its applications. This biennial conference presents the critical advances in basic, clinical and operational HIV research that move science into policy and practice. Through its open and inclusive programme, the meeting sets the gold standard of HIV science, featuring highly diverse and cutting-edge research.
  
  - IAS 2023, the 12th IAS Conference on HIV Science, will take place in Brisbane, Australia, and virtually from July 23-26, 2023.

### The Ryan White HIV/AIDS Program Clinical Conference

- **Description**
  
  - The RWHAP Clinical Conference provides state-of-the-art updates on research, care, and treatment issues in the medical management of HIV infection for experienced HIV clinical decision makers.
  
  - The RWHAP Clinical Conference is planned with and supported by the HIV/AIDS Bureau, Health Resources and Services Administration of the US Department of Health and Human Services (HRSA) and is sponsored and organized by the International Antiviral Society-USA (IAS-USA). This conference is coordinated through the RWHAP AIDS Education and Training Centers (AETC) clinician training network. A mix of lectures, case-based interactive presentations, and small-group workshop breakout sessions will be held during the 3 days of the RWHAP Clinical Conference.